Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Disorders of Hemostasis01:24

Disorders of Hemostasis

885
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
885

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Preimplantation Genetic Testing for Families at Risk of Haemophilia: Ten-Year Single-Centre Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome.

American journal of hematology·2026
Same author

Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Journal of clinical medicine·2026
Same author

Sex Differences in Cancer-Associated Thrombosis.

International journal of molecular sciences·2026
Same author

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Clinical chemistry and laboratory medicine·2026

相关实验视频

Updated: Jun 29, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K

在Emicizumab预防期间自发性关节出血的预测参数

Sara Arcudi1, Roberta Gualtierotti1,2, Erica Scalambrino1

  • 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

Blood advances
|March 26, 2024
PubMed
概括

关节健康评分,而不是实验室测试,可以预测血友病A患者的自发出血. 鼻膜炎和较高的HEAD-US分数可以识别那些风险较高的人.

更多相关视频

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

7.5K

相关实验视频

Last Updated: Jun 29, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.8K
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

7.5K

科学领域:

  • 血液学 血液学 血液学
  • 凝血障碍 凝血障碍 凝血障碍
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 艾米齐祖马布预防对血友病A (HA) 有效,但并不能消除所有出血事件.
  • 需要工具来识别患有自发关节出血风险的艾米齐祖马布的HA患者.

研究的目的:

  • 评估实验室标记或关节病得分是否预测HA患者接受埃米齐祖马布的自发关节出血.

主要方法:

  • 在40名接受埃米齐祖马布治疗的严重HA患者的观察队列研究.
  • 评估了全球凝血测试,艾米齐祖马布水平,血友病关节健康评分和HEAD-US评分.
  • 使用考克斯回归和ROC分析来确定自发关节出血的预测因素.

主要成果:

  • 没有实验室参数预测自发关节出血.
  • 突炎和较高的HEAD-US得分与增加的出血风险显著相关 (AUC=0.84).

结论:

  • 关节评估得分,特别是突炎和HEAD-US,可以预测艾米齐祖马布预防HA患者的自发关节出血.
  • 实验室标记物不足以在这个人群中进行风险分层.